Gary Clark: Unfiltered

From AI security to quantum navigation, VetsinTech's latest finalists reveal a powerful trend: veteran founders are building tomorrow's critical infrastructure.

On the 14th anniversary of his abduction in Syria, the call to free Austin Tice grows louder, yet the journalist and veteran remains missing.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

TestMu AI's massive virtual conference isn't just about code. It's a strategic play to own the critical, high-stakes market of validating what AI builds.

Bonerge is betting that cellular recovery is the key to mitigating the high cost of night shift work. Its real-world trial could redefine human capital investment.

With federal loans for med students cut, AACOM's new Sallie Mae deal fills a vital gap. But does this private-sector solution come at too high a price?

The footwear giant just launched a mascot, but this isn't child's play. It's a calculated pivot from fleeting collabs to building a scalable, long-term asset.

Revenue is down, but Bragg Gaming's margins are up. A new chairman, a major acquisition, and deep cuts signal a high-stakes bet on a leaner future.

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

Record shareholder returns and massive cash flow paint a rosy picture, but a deeper look at Pan American's Q2 results reveals operational stumbles.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

A legacy battery gets a high-tech upgrade. AGY and Terra Supreme are using advanced glass fibers to give lead-acid a new lease on life, challenging lithium.

Last Mile Health's Hilton Prize isn't charity. It's a strategic investment in a sustainable, localized economic model that de-risks healthcare delivery.

A posthumous memoir from a NASA pioneer reveals how frontier ingenuity built a strategic asset in Alaska, a story more relevant than ever in 2026.

Saleo's #127 Inc. 5000 rank and acquisition by Consensus isn't just a growth story. It's proof that the B2B buying experience has fundamentally changed.

A 120-year-old bank and a federal program invest $100,000 in Orrick, MO. It's more than charity; it's a powerful model for rural America's future.

The USTA's inaugural Coaches Open isn't just a conference; it's a strategic investment in the human infrastructure needed to sustain tennis's record growth.

As trust in institutions wanes, how is value created? A top surgeon's recent accolade reveals the powerful economic engine of peer-validated expertise.

Entertainment Partners' deal with NYU Tisch is more than a donation; it's a strategic move to wire cost-discipline into the DNA of tomorrow's filmmakers.

Stand Up To Cancer funds a bold new strategy against pancreatic cancer, pairing an mRNA vaccine with cellular therapy to finally target the elusive KRAS gene.